Drug Augmentation Strategies for Treatment- Resistant Obsessive- Compulsive and Related Disorders

Nenhuma Miniatura disponível
Citações na Scopus
Tipo de produção
Data de publicação
Título da Revista
ISSN da Revista
Título do Volume
Shavitt, R. G.; Diniz, J. B.. Drug Augmentation Strategies for Treatment- Resistant Obsessive- Compulsive and Related Disorders. In: . A TRANSDIAGNOSTIC APPROACH TO OBSESSIONS, COMPULSIONS AND RELATED PHENOMENA: CAMBRIDGE UNIVERSITY PRESS, 2019. p.229-241.
Projetos de Pesquisa
Unidades Organizacionais
  1. Bandelow, B., Zohar, J., Hollander, E., World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders-first revision (2008) World J Biol Psychiatry, 9 (4), pp. 248-312
  2. Hollander, E., Allen, A., Kwon, J., Clomipramine vs desipramine crossover trial in body dysmorphic disorder: Selective efficacy of a serotonin reuptake inhibitor in imagined ugliness (1999) Arch Gen Psychiatry, 56 (11), pp. 1033-1039
  3. Johnson, J., El-Alfy, A.T., Review of available studies of the neurobiology and pharmacotherapeutic management of trichotillomania (2016) J Adv Res, 7 (2), pp. 169-184
  4. Brakoulias, V., Eslick, G.D., Starcevic, V., A metaanalysis of the response of pathological hoarding to pharmacotherapy (2015) Psychiatry Res, 229 (1-2), pp. 272-276
  5. Mataix-Cols, D., Fernández de la Cruz, L., Nordsletten, A.E., Lenhard, F., Isomura, K., Simpson, H.B., Towards an international expert consensus for defining treatment response, remission, recovery and relapse in obsessive-compulsive disorder (2016) World Psychiatry, 15 (1), pp. 80-81
  6. Belotto-Silva, C., Diniz, J.B., Malavazzi, D.M., Group cognitive-behavioral therapy versus selective serotonin reuptake inhibitors for obsessive-compulsive disorder: A practical clinical trial (2012) J Anxiety Disord, 26 (1), pp. 25-31
  7. Diniz, J.B., Shavitt, R.G., Fossaluza, V., Koran, L., de Braganca Pereira, C.A., Miguel, E.C., A double-blind, randomized, controlled trial of fluoxetine plus quetiapine or clomipramine versus fluoxetine plus placebo for obsessive-compulsive disorder (2011) J Clin Psychopharmacol, 31 (6), pp. 763-768
  8. Jakubovski, E., Diniz, J.B., Valério, C., Clinical predictors of long-term outcome in obsessive-compulsive disorder (2013) Depress Anxiety, 30 (8), pp. 763-772
  9. Costa, D.L., Diniz, J.B., Miguel, E.C., How similar are the disorders included under the umbrella of obsessivecompulsive disorder and related disorders? (2016) JAMA Psychiatry, 73 (8), p. 877
  10. Foa, E.B., Simpson, H.B., Liebowitz, M.R., Six-month follow-up of a randomized controlled trial augmenting serotonin reuptake inhibitor treatment with exposure and ritual prevention for obsessive-compulsive disorder (2013) J Clin Psychiatry, 74 (5), pp. 464-469
  11. Simpson, H.B., Foa, E.B., Liebowitz, M.R., Cognitivebehavioral therapy vs risperidone for augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: A randomized clinical trial (2013) JAMA Psychiatry, 70 (11), pp. 1190-1199
  12. Keuthen, N.J., Tung, E.S., Reese, H.E., Raikes, J., Lee, L., Mansueto, C.S., Getting the word out: Cognitivebehavioral therapy for trichotillomania (hair-pulling disorder) and excoriation (skin-picking) disorder (2015) Ann Clin Psychiatry, 27 (1), pp. 10-15
  13. Williams, M., Viscusi, J.A., Hoarding disorder and a systematic review of treatment with cognitive behavioral therapy (2016) Cogn Behav Ther, 45 (2), pp. 93-110
  14. Pampaloni, I., Sivakumaran, T., Hawley, C., Highdose selective serotonin reuptake inhibitors in OCD: A systematic retrospective case notes survey (2010) J Psychopharmacol, 24 (10), pp. 1439-1445
  15. Math, S., Janardhan Reddy, Y., Issues in the pharmacological treatment of obsessive-compulsive disorder (2007) Int J Clin Pract, 61 (7), pp. 1188-1197
  16. Simeon, J., Thatte, S., Wiggins, D., Treatment of adolescent obsessive-compulsive disorder with a clomipraminefluoxetine combination (1990) Psychopharmacol Bull, 26 (3), pp. 285-290
  17. Browne, M., Horn, E., Jones, T., The benefits of clomipramine-fluoxetine combination in obsessive compulsive disorder (1993) Can J Psychiatry, 38 (4), pp. 242-243
  18. Diniz, J.B., Shavitt, R.G., Pereira, C.A.B., Quetiapine versus clomipramine in the augmentation of selective serotonin reuptake inhibitors for the treatment of obsessive-compulsive disorder: A randomized, openlabel trial (2010) J Psychopharmacol, 24 (3), pp. 297-307
  19. Ravizza, L., Barzega, G., Bellino, S., Bogetto, F., Maina, G., Drug treatment of obsessive-compulsive disorder (OCD): Long-term trial with clomipramine and selective serotonin reuptake inhibitors (SSRIs) (1996) Psychopharmacol Bull, 32 (1), pp. 167-173
  20. Pallanti, S., Quercioli, L., Paiva, R., Koran, L., Citalopram for treatment-resistant obsessive-compulsive disorder (1999) Eur Psychiatry, 14 (2), pp. 101-106
  21. Marazziti, D., Golia, F., Consoli, G., Effectiveness of long-term augmentation with citalopram to clomipramine in treatment-resistant OCD patients (2008) CNS Spectr, 13 (11), pp. 971-976
  22. Andrade, C., Augmenting selective serotonin reuptake inhibitors with clomipramine in obsessive-compulsive disorder: Benefits and risks (2013) J Clin Psychiatry, 74 (12), pp. e1128-e1133
  23. Diniz, J.B., Costa, D.L., Cassab, R.C., Pereira, C.A., Miguel, E.C., Shavitt, R.G., The impact of comorbid body dysmorphic disorder on the response to sequential pharmacological trials for obsessive-compulsive disorder (2013) J Psychopharmacol, 28 (6), pp. 603-611
  24. Trivedi, M.H., Fava, M., Wisniewski, S.R., Medication augmentation after the failure of SSRIs for depression (2006) N Engl J Med, 354 (12), pp. 1243-1252
  25. Alevizos, B., Lykouras, L., Zervas, I., Christodoulou, G., Risperidone-induced obsessive-compulsive symptoms: A series of six cases (2002) J Clin Psychopharmacol, 22 (5), pp. 461-467
  26. Alevizos, B., Papageorgiou, C., Christodoulou, G., Obsessive-compulsive symptoms with olanzapine (2004) Int J Neuropsychopharmacol, 7 (3), pp. 375-377
  27. Ercan, E.S., Ardic, U.A., Ercan, E., Yuce, D., Durak, S., A promising preliminary study of aripiprazole for treatment-resistant childhood obsessive-compulsive disorder (2015) J Child Adolesc Psychopharmacol, 25 (7), pp. 580-584
  28. Bloch, M., Landeros-Weisenberger, A., Kelmendi, B., Coric, V., Bracken, M., Leckman, J., A systematic review: Antipsychotic augmentation with treatment refractory obsessive-compulsive disorder (2006) Mol Psychiatry, 11 (7), pp. 622-632
  29. Albert, U., Carmassi, C., Cosci, F., Role and clinical implications of atypical antipsychotics in anxiety disorders, obsessive-compulsive disorder, trauma-related, and somatic symptom disorders: A systematized review (2016) Int Clin Psychopharmacol, 31 (5), pp. 249-258
  30. Kim, C., Koo, M., Cheon, K., Ryu, Y., Lee, J., Lee, H., Dopamine transporter density of basal ganglia assessed with [123I]IPT SPET in obsessive-compulsive disorder (2003) Eur J Nucl Med Mol Imaging, 30 (12), pp. 1637-1643
  31. van der Wee, N., Stevens, H., Hardeman, J., Enhanced dopamine transporter density in psychotropic-naive patients with obsessive-compulsive disorder shown by [123I]{beta}-CIT SPECT (2004) Am J Psychiatry, 161 (12), pp. 2201-2206
  32. Cheon, K.A., Ryu, Y.H., Namkoong, K., Kim, C.H., Kim, J.J., Lee, J.D., Dopamine transporter density of the basal ganglia assessed with [123I]IPT SPECT in drug-naïve children with Tourette’s disorder (2004) Psychiatry Res, 130 (1), pp. 85-95
  33. Winogrodzka, A., Bergmans, P., Booij, J., van Royen, E.A., Stoof, J.C., Wolters, E.C., [(123)I]beta-CIT SPECT is a useful method for monitoring dopaminergic degeneration in early stage Parkinson’s disease (2003) J Neurol Neurosurg Psychiatry, 74 (3), pp. 294-298
  34. Dell’Osso, B., Altamura, A.C., Allen, A., Marazziti, D., Hollander, E., Epidemiologic and clinical updates on impulse control disorders: A critical review (2006) Eur Arch Psychiatry Clin Neurosci, 256 (8), pp. 464-475
  35. Denys, D., Klompmakers, A., Westenberg, H., Synergistic dopamine increase in the rat prefrontal cortex with the combination of quetiapine and fluvoxamine (2004) Psychopharmacology (Berl), 176 (2), pp. 195-203
  36. Zhang, W., Perry, K., Wong, D., Synergistic effects of olanzapine and other antipsychotic agents in combination with fluoxetine on norepinephrine and dopamine release in rat prefrontal cortex (2000) Neuropsychopharmacology, 23 (3), pp. 250-262
  37. McDougle, C., Goodman, W., Leckman, J., Lee, N., Heninger, G., Price, L., Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics (1994) Arch Gen Psychiatry, 51 (4), pp. 302-308
  38. McDougle, C., Goodman, W., Price, L., Neuroleptic addition in fluvoxamine-refractory obsessive-compulsive disorder (1990) A m J Psychiatry, 147 (5), pp. 652-654
  39. Srour, M., Lespérance, P., Richer, F., Chouinard, S., Psychopharmacology of tic disorders (2008) J Can Acad Child Adolesc Psychiatry, 17 (3), pp. 150-159
  40. Van Ameringen, M., Mancini, C., Oakman, J.M., Farvolden, P., The potential role of haloperidol in the treatment of trichotillomania (1999) J Affect Disord, 56 (2-3), pp. 219-226
  41. Dold, M., Aigner, M., Lanzenberger, R., Kasper, S., Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: An update meta-analysis of doubleblind, randomized, placebo-controlled trials (2015) Int J Neuropsychopharmacol, 18 (9). , pii: pyv047
  42. Van Ameringen, M., Mancini, C., Patterson, B., Bennett, M., Oakman, J., A randomized, doubleblind, placebo-controlled trial of olanzapine in the treatment of trichotillomania (2010) J Clin Psychiatry, 71 (10), pp. 1336-1343
  43. Rothbart, R., Stein, D.J., Pharmacotherapy of trichotillomania (hair pulling disorder): An updated systematic review (2014) Expert Opin Pharmacother, 15 (18), pp. 2709-2719
  44. Turner, G.A., Sutton, S., Sharma, A., Augmentation of venlafaxine with aripiprazole in a case of treatmentresistant excoriation disorder (2014) Innov Clin Neurosci, 11 (1-2), pp. 29-31
  45. Luca, M., Vecchio, C., Luca, A., Calandra, C., Haloperidol augmentation of fluvoxamine in skin picking disorder: A case report (2012) J Med Case Rep, 6, p. 219
  46. Phillips, K.A., Placebo-controlled study of pimozide augmentation of fluoxetine in body dysmorphic disorder (2005) Am J Psychiatry, 162 (2), pp. 377-379
  47. Phillips, K.A., Olanzapine augmentation of fluoxetine in body dysmorphic disorder (2005) Am J Psychiatry, 162 (5), pp. 1022-1023
  48. Nakaaki, S., Murata, Y., Furukawa, T.A., Efficacy of olanzapine augmentation of paroxetine therapy in patients with severe body dysmorphic disorder (2008) Psychiatry Clin Neurosci, 62 (3), p. 370
  49. Matsunaga, H., Nagata, T., Hayashida, K., Ohya, K., Kiriike, N., Stein, D., A long-term trial of the effectiveness and safety of atypical antipsychotic agents in augmenting SSRI-refractory obsessive-compulsive disorder (2009) J Clin Psychiatry, 70 (6), pp. 863-868
  50. Cortese, B., Phan, K., The role of glutamate in anxiety and related disorders (2005) CNS Spectr, 10 (10), pp. 820-830
  51. Bhattacharyya, S., Chakraborty, K., Glutamatergic dysfunction: Newer targets for anti-obsessional drugs (2007) Recent Pat CNS Drug Discov, 2 (1), pp. 47-55
  52. Stewart, S., Fagerness, J., Platko, J., Association of the SLC1A1 glutamate transporter gene and obsessivecompulsive disorder (2007) Am J Med Genet B Neuropsychiatr Genet, 144B (8), pp. 1027-1033
  53. Qin, H., Samuels, J.F., Wang, Y., Whole-genome association analysis of treatment response in obsessive-compulsive disorder (2016) Mol Psychiatry, 21 (2), pp. 270-276
  54. Pittenger, C., Glutamate modulators in the treatment of obsessive-compulsive disorder (2015) Psychiatr Ann, 45 (6), pp. 308-315
  55. Afshar, H., Roohafza, H., Mohammad-Beigi, H., N-acetylcysteine add-on treatment in refractory obsessive-compulsive disorder: A randomized, doubleblind, placebo-controlled trial (2012) J Clin Psychopharmacol, 32 (6), pp. 797-803
  56. Paydary, K., Akamaloo, A., Ahmadipour, A., Pishgar, F., Emamzadehfard, S., Akhondzadeh, S., N-acetylcysteine augmentation therapy for moderate-to-severe obsessive-compulsive disorder: Randomized, doubleblind, placebo-controlled trial (2016) J Clin Pharm Ther, 41 (2), pp. 214-219
  57. Sarris, J., Oliver, G., Camfield, D.A., N-acetyl cysteine (NAC) in the treatment of obsessivecompulsive disorder: A 16-week, double-blind, randomised, placebo-controlled study (2015) CNS Drugs, 29 (9), pp. 801-809
  58. Grant, J.E., Odlaug, B.L., Kim, S.W., N-acetylcysteine, a glutamate modulator, in the treatment of trichotillomania: A double-blind, placebo-controlled study (2009) Arch Gen Psychiatry, 66 (7), pp. 756-763
  59. Grant, J.E., Chamberlain, S.R., Redden, S.A., Leppink, E.W., Odlaug, B.L., Kim, S.W., N-acetylcysteine in the treatment of excoriation disorder: A randomized clinical trial (2016) JAMA Psychiatry, 73 (5), pp. 490-496
  60. Donegan, S., Dixon, P., Hemming, K., Tudur-Smith, C., Marson, A., A systematic review of placebo-controlled trials of topiramate: How useful is a multiple-indications review for evaluating the adverse events of an antiepileptic drug? (2015) Epilepsia, 56 (12), pp. 1910-1920
  61. Shank, R.P., Gardocki, J.F., Streeter, A.J., Maryanoff, B.E., An overview of the preclinical aspects of topiramate: Pharmacology, pharmacokinetics, and mechanism of action (2000) Epilepsia, 41, pp. S3-S9
  62. Berlin, H., Koran, L., Jenike, M., Double-blind, placebo-controlled trial of topiramate augmentation in treatment-resistant obsessive-compulsive disorder (2011) J Clin Psychiatry, 72 (5), pp. 716-721
  63. Jankovic, J., Jimenez-Shahed, J., Brown, L.W., A randomised, double-blind, placebo-controlled study of topiramate in the treatment of Tourette syndrome (2010) J Neurol Neurosurg Psychiatry, 81 (1), pp. 70-73
  64. Lochner, C., Seedat, S., Niehaus, D.J., Stein, D.J., Topiramate in the treatment of trichotillomania: An open-label pilot study (2006) Int Clin Psychopharmacol, 21 (5), pp. 255-259
  65. Jafferany, M., Osuagwu, F.C., Use of topiramate in skinpicking disorder: A pilot study (2017) Prim Care Companion CNS Disord, 19 (1)
  66. Jafferany, M., Shireen, F., Ibrahim, A., An open-label trial of topiramate in the treatment of skin picking in pervasive developmental disorder not otherwise specified (2010) Prim Care Companion J Clin Psychiatry, 12 (2). , pii: PCC.09l00829
  67. Katoh-Semba, R., Asano, T., Ueda, H., Riluzole enhances expression of brain-derived neurotrophic factor with consequent proliferation of granule precursor cells in the rat hippocampus (2002) FASEB J, 16 (10), pp. 1328-1330
  68. Pittenger, C., Bloch, M.H., Wasylink, S., Riluzole augmentation in treatment-refractory obsessive-compulsive disorder: A pilot randomized placebo-controlled trial (2015) J Clin Psychiatry, 76 (8), pp. 1075-1084
  69. Emamzadehfard, S., Kamaloo, A., Paydary, K., Riluzole in augmentation of fluvoxamine for moderate to severe obsessive compulsive disorder: Randomized, double-blind, placebo-controlled study (2016) Psychiatry Clin Neurosci, 70 (8), pp. 332-341
  70. Grant, P.J., Joseph, L.A., Farmer, C.A., 12-week, placebo-controlled trial of add-on riluzole in the treatment of childhood-onset obsessivecompulsive disorder (2014) Neuropsychopharmacology, 39 (6), pp. 1453-1459
  71. Lemmon, M.E., Grados, M., Kline, T., Thompson, C.B., Ali, S.F., Singer, H.S., Efficacy of glutamate modulators in tic suppression: A double-blind, randomized control trial of d-serine and riluzole in Tourette syndrome (2015) Pediatr Neurol, 52 (6), pp. 629-634
  72. Coric, V., Kelmendi, B., Pittenger, C., Wasylink, S., Bloch, M.H., Green, J., Beneficial effects of the antiglutamatergic agent riluzole in a patient diagnosed with trichotillomania (2007) J Clin Psychiatry, 68 (1), pp. 170-171
  73. Sasso, D.A., Kalanithi, P.S., Trueblood, K.V., Beneficial effects of the glutamate-modulating agent riluzole on disordered eating and pathological skin-picking behaviors (2006) J Clin Psychopharmacol, 26 (6), pp. 685-687
  74. Reid, J.G., Gitlin, M.J., Altshuler, L.L., Lamotrigine in psychiatric disorders (2013) J Clin Psychiatry, 74 (7), pp. 675-684
  75. Bruno, A., Micò, U., Pandolfo, G., Lamotrigine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: A double-blind, placebo-controlled study (2012) J Psychopharmacol, 26 (11), pp. 1456-1462
  76. Bloom, R., Amber, K.T., Identifying the incidence of rash, Stevens-Johnson syndrome and toxic epidermal necrolysis in patients taking lamotrigine: A systematic review of 122 randomized controlled trials (2017) An Bras Dermatol, 92 (1), pp. 139-141
  77. Plosker, G.L., Lyseng-Williamson, K.A., Memantine: A pharmacoeconomic review of its use in moderateto- severe Alzheimer’s disease (2005) Pharmacoeconomics, 23 (2), pp. 193-206
  78. Ghaleiha, A., Entezari, N., Modabbernia, A., Memantine add-on in moderate to severe obsessive-compulsive disorder: Randomized doubleblind placebo-controlled study (2013) J Psychiatr Res, 47 (2), pp. 175-180
  79. Bartoli, F., Riboldi, I., Crocamo, C., Di Brita, C., Clerici, M., Carrà, G., Ketamine as a rapid-acting agent for suicidal ideation: A meta-analysis (2017) Neurosci Biobehav Rev, 77, pp. 232-236
  80. Rodriguez, C.I., Kegeles, L.S., Levinson, A., Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: Proof-of-concept (2013) Neuropsychopharmacology, 38 (12), pp. 2475-2483
  81. Rodriguez, C.I., Wheaton, M., Zwerling, J., Can exposure-based CBT extend the effects of intravenous ketamine in obsessive-compulsive disorder? An openlabel trial (2016) J Clin Psychiatry, 77 (3), pp. 408-409
  82. Andrade, C., Ondansetron augmentation of serotonin reuptake inhibitors as a treatment strategy in obsessive-compulsive disorder (2015) J Clin Psychiatry, 76 (1), pp. e72-e75
  83. Askari, N., Moin, M., Sanati, M., Granisetron adjunct to fluvoxamine for moderate to severe obsessive-compulsive disorder: A randomized, double-blind, placebo-controlled trial (2012) CNS Drugs, 26 (10), pp. 883-892
  84. Shalbafan, M., Mohammadinejad, P., Shariat, S.V., Celecoxib as an adjuvant to fluvoxamine in moderate to severe obsessive-compulsive disorder: A double-blind, placebo-controlled, randomized trial (2015) Pharmacopsychiatry, 48 (4-5), pp. 136-140
  85. Koran, L., Aboujaoude, E., Bullock, K., Franz, B., Gamel, N., Elliott, M., Double-blind treatment with oral morphine in treatment-resistant obsessive-compulsive disorder (2005) J Clin Psychiatry, 66 (3), pp. 353-359
  86. Hamon, M., Blier, P., Monoamine neurocircuitry in depression and strategies for new treatments (2013) Prog Neuropsychopharmacol Biol Psychiatry, 45, pp. 54-63
  87. Kennedy, S.H., Rizvi, S.J., Emerging drugs for major depressive disorder (2009) Expert Opin Emerg Drugs, 14 (3), pp. 439-453
  88. Grados, M., Prazak, M., Saif, A., Halls, A., A review of animal models of obsessive-compulsive disorder: A focus on developmental, immune, endocrine and behavioral models (2016) Expert Opin Drug Discov, 11 (1), pp. 27-43
  89. Cobb, J., Behaviour therapy in phobic and obsessional disorders (1983) Psychiatr Dev, 1 (4), pp. 351-365
  90. Manos, R.C., Cahill, S.P., Wetterneck, C.T., Conelea, C.A., Ross, A.R., Riemann, B.C., The impact of experiential avoidance and obsessive beliefs on obsessivecompulsive symptoms in a severe clinical sample (2010) J Anxiety Disord, 24 (7), pp. 700-708
  91. Katz, D., Rector, N.A., Laposa, J.M., The interaction of distress tolerance and intolerance of uncertainty in the prediction of symptom reduction across CBT for social anxiety disorder (2017) Cogn Behav Ther, pp. 1-19
  92. Costa, D.L.D.C., Barbosa, V.S., Requena, G., Shavitt, R.G., Pereira, C.A.B., Diniz, J.B., Dissecting the Yale-Brown Obsessive-Compulsive Scale severity scale to understand the routes for symptomatic improvement in obsessive-compulsive disorder (2017) J Psychopharmacol, 31 (10), pp. 1312-1322
  93. Conceição, C.D.L., Chagas, A.M., Arzeno, F.Y., Body dysmorphic disorder in patients with obsessivecompulsive disorder: Prevalence and clinical correlates (2012) Depress Anxiety, 29 (11), pp. 966-975
  94. Kelly, M.M., Walters, C., Phillips, K.A., Social anxiety and its relationship to functional impairment in body dysmorphic disorder (2010) Behav Ther, 41 (2), pp. 143-153
  95. (2013) Diagnostic and Statistical Manual of Mental Disorders, , 5th ed. Washington, DC: APA
  96. Bohne, A., Savage, C.R., Deckersbach, T., Keuthen, N.J., Wilhelm, S., Motor inhibition in trichotillomania and obsessive-compulsive disorder (2008) J Psychiatr Res, 42 (2), pp. 141-150
  97. Chamberlain, S., Odlaug, B., Boulougouris, V., Fineberg, N., Grant, J., Trichotillomania: Neurobiology and treatment (2009) Neurosci Biobehav Rev, 33 (6), pp. 831-842
  98. Christenson, G.A., Mackenzie, T.B., Trichotillomania, body dysmorphic disorder, and obsessive-compulsive disorder (1995) J Clin Psychiatry, 56 (5), pp. 211-212
  99. Arnold, L., Auchenbach, M., McElroy, S., Psychogenic excoriation. Clinical features, proposed diagnostic criteria, epidemiology and approaches to treatment (2001) CNS Drugs, 15 (5), pp. 351-359
  100. McGuire, J.F., Wu, M.S., Piacentini, J., McCracken, J.T., Storch, E.A., A meta-analysis of d-cycloserine in exposure-based treatment: Moderators of treatment efficacy, response, and diagnostic remission (2017) J Clin Psychiatry, 78 (2), pp. 196-206
  101. Song, C., Stevenson, C.W., Guimarães, F.S., Lee, J.L., Bidirectional effects of cannabidiol on contextual fear memory extinction (2016) Front Pharmacol, 7, p. 493
  102. Jurkus, R., Day, H.L., Guimarães, F.S., Lee, J.L., Bertoglio, L.J., Stevenson, C.W., Cannabidiol regulation of learned fear: Implications for treating anxietyrelated disorders (2016) Front Pharmacol, 7, p. 454
  103. Wang, Y., Zhang, X., FAAH inhibition produces antidepressant-like efforts of mice to acute stress via synaptic long-term depression (2017) Behav Brain Res, 324, pp. 138-145